N/A N=33 The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years
Upper Respiratory Infection · Common Cold
Primary: Local Leukotriene Levels — 440; 368; 440; 619 pg/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=58 The Development of a Human Model of Respiratory Syncytial Virus Infection
Respiratory Syncytial Virus Infections · Respiratory Viral Infections
Primary: Host Response to RSV Challenge Measured as Change From Baseline of Chemical Mediators in Nasal Fluid — 23 Participants
N/A N=26 Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic
Asthma
Primary: Airway Symptom Scores Experienced by Subjects During the 1st 4 Days of the Infection — 8.72; 2.77 units on a scale — p=0.049
N/A N=272 Collection and Testing of Respiratory Samples
QIAGEN ResPlex II Advanced Panel · Influenza A · Respiratory Syncytial Virus Infections
Primary: Detection of Respiratory Viruses — 83 participants
Phase 2 N=38 Clinical Response to Rhinovirus Challenge
Asthma · Allergic Rhinitis
Primary: Change in Symptom Scores Induced by the Rhinovirus Using Jackson Criteria Including Nasal Congestion, Drainage, Cough, Wheezing — 5.0; 4.2; 2.8 score on a scale
N/A N=75 Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge
Respiratory Syncytial Virus Infections · Influenza, Human
Primary: Total Symptom Score — 29.25; 17.50; 11.00; 13.00 score on a scale
N/A N=127 Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
Respiratory Disorders
Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year
Phase 4 N=18 Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)
Influenza
Primary: Number of Participants From Each Arm Who Received Influenza Vaccine — 0; 17 Participants
N/A N=360 Urgent Care Management of Respiratory Illness Enabled With Novel Testing Pathway
Viral Infection · Acute Respiratory Infection · Upper Resp Tract Infection
Primary: Satisfaction With Time to Receive Result — 180; 53; 3; 72 participants
N/A N=91 Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children
Respiratory Syncytial Virus Infection
Primary: Nasal Interferon (IFN)-a2 — 10; 26 pg/ml — p=0.04
Phase 3 N=240 Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral Infection
Viral Respiratory Infection
Primary: Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms — 4.1; 5.0 days — p=0.0155
Phase 1 N=4 Challenge Infection of Healthy Adult Volunteers With RSV A2
Upper Respiratory Tract Infections
Primary: Participants With Detectable RSV Shedding in Nasopharyngeal Wash — 2; 4 Participants
N/A N=25 Effect of Montelukast on Experimentally-Induced RV16 Infection in Asthma
Asthma
Primary: Mean Asthma Symptom Score — 2.3; 2.1 Asthma symptom score
N/A N=9,151 Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.
Healthy
Primary: Change From Baseline in Self-Reported Symptom Scores From Well-to-Sick State Through Day 56 — 0.065; 0.281; 0.036; 0.113 Scores on a scale — p=<.0001
N/A N=59 Assessment of Airway Obstruction in Infants With Lower Respiratory Infections
Bronchiolitis · Respiratory Syncytial Virus Infections
Primary: Lung Function — 0.071; -3.179; 0.186; -3.345 Z score — p=0.0020
N/A N=194 Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department
Respiratory Tract Infections · Influenza, Human · Common Cold
Primary: Proportion of Patients Receiving Antibiotics or a Prescription for Antibiotics in the ED — 20; 33 Participants
Phase 4 N=50 Intermittent Use of Aerosolized Ribavirin for Treatment of RSV
Hematological Malignancies
Primary: Occurrences of Pneumonia — 4; 3 Participants
Phase 2 N=98 Human Lung Responses to Respiratory Pathogens
Respiratory Infection
Primary: Antimicrobial Activity by Airway Surface Liquid (ASL) as Measured by Relative Light Units (RLU) — -581; -485 Relative Light Units (RLU)
Phase 2 N=260 Nitazoxanide Versus Placebo for the Treatment of Hospitalized Subjects With Severe Acute Respiratory Illness
Severe Acute Respiratory Illness
Primary: Time to Hospital Discharge — 7.1; 7.5 Days — p=0.5634
Phase 2 N=31 Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus
Asthma
Primary: Airway Symptom Scores Experienced by Participants During the First 4 Days of the Acute Infection. — 4.0; 3.3 units on a scale — p=0.59
Phase 2 N=44 Respiratory Syncytial Virus - RSV Protocol
Bone Marrow Transplant Infection · Infection in Marrow Transplant Recipients · Respiratory Syncytial Virus Infections
Primary: Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI) — 8; 30; 10 percentage of participants
Phase 4 N=204 Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections
Acute Respiratory Viral Infections
Primary: Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms. — 4.1; 4.5 days — p=0.032
N/A N=20 Novel Mucosal Correlates Of RSV Protection In Older Adults
Respiratory Tract Infections
Primary: Number of Solicited and Unsolicited Adverse Events (AEs) — 17 adverse events
Phase 4 N=84 Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds
Upper Respiratory Infection
Primary: Nasal Secretion Weights — 3.5; 4.2; 1.2; 2.6 grams
N/A N=190 Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)
Common Cold
Primary: Interleukin-8 (IL-8) — 133; 122 pg/ml
N/A N=48 Cohort Isolation and Cross-infection in Bronchiolitis
Bronchiolitis
Primary: Duration of Hospital Stay — 3.9; 2.1 days
N/A N=4,561 Influenza Resistance Information Study
Influenza
Primary: Number of Participants With Genotypic Resistance — 44; 1; 0; 2 participants
N/A N=94 A Pilot Study of the Safety, Tolerability, and Effectiveness of Halo
Healthy
Primary: Number of Participants That Develop Acute Respiratory Illnesses When Using Halo vs Placebo — 2; 4 participants
N/A N=152 Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis
Bronchiolitis · Bronchiolitis, Viral · RSV Infection
Primary: The Number of Sampling Visits on Which Participants Are Willing to Undergo Nasosorption and/or NPA Sampling — 124; 60; 0; 0 Sampling visits
Phase 2 N=16 Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients
Lung Transplant Infection
Primary: Number of Participants Free From New or Progressive Chronic Lung Allograft Dysfunction — 2; 4 Participants